Sanofi India Limited has informed the Exchange regarding appointment of Mr. Mahadev Gawade as an Additional and Whole-time Director of the Company w.e.f. August 11, 2025.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India's board met on July 31, 2025 and approved unaudited financial results for the quarter and half-year ended June 30, 2025. Q1 revenue from operations stood at Rs 4,063 million, down from Rs 4,635 million a year ago, while profit before tax rose to Rs 941 million (vs Rs 921 million). Half-year revenue came in at Rs 9,422 million with profit before tax of Rs 2,594 million, up from Rs 1,966 million. The board also noted the retirement of Ms. Renee Amonkar as Whole-time Director and Site Director - Goa effective August 11, 2025, and approved the appointment of Mr. Mahadev Gawade as Additional and Whole-time Director for three years from the same date, along with the role of Site Director - Goa. Separately, the company disclosed a new promotion and distribution agreement with Emcure Pharmaceuticals for its oral anti-diabetic (OAD) business.
A routine leadership change at the Goa manufacturing operations, with no governance red flags. Q1 revenue softened year-on-year but margins improved, and the new Emcure partnership for diabetes products could support future growth. Shareholders should watch for Q1 results commentary and shareholder approval of Mr. Gawade's appointment at the next AGM.